New cell therapy GT719 targets tough blood cancers in early trial

NCT ID NCT06948981

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a single injection of GT719 and are monitored for side effects and cancer response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT719 injection (a type of cell therapy targeting CD19-positive cancer cells)
What this could lead to: If successful, this could offer a new treatment option for patients with hard-to-treat B-cell blood cancers that have not responded to standard therapies.
What could go wrong: This is an early-phase trial with only 46 participants, so results may not apply broadly. Cell therapies can cause serious side effects like cytokine release syndrome or nervous system problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-cell non-Hodgkin lymphoma hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.